Drug Approval | August 12, 2021
Human studies begin on AI discovered COVID-19 treatment with up to 97% effectiveness
A treatment to prevent extreme symptoms and cut hospitalisation
A treatment to prevent extreme symptoms and cut hospitalisation
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The company is eligible for 12 months exclusivity from launch
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
The American Association for Clinical Chemistry (AACC); the American Society for Clinical Pathology (ASCP); the American Society of Hematology (ASH); and the International Myeloma Working Group (IMWG), collaborate to develop the guideline
OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
The aim is to create new genomics solutions that could combat cancer and advance market access
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
